JCR Pharmaceuticals Co., Ltd.

The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is projected to grow at a CAGR of 5.9% to USD 5,014.5 million by 2035. Growth is driven by advancements in biotechnology, enhanced diagnostic methods, increased awareness, and the availability of enzyme replacement therapy. Clinical trials for innovative treatments are expanding, despite high costs and lack of reimbursement policies limiting market growth.

The global mucopolysaccharidosis (MPS) treatment market, valued at USD 2,669.1 million in 2024, is projected to grow at a CAGR of 5.9% to USD 5,014.5 million by 2035. Growth drivers include advancements in biotechnology, enhanced diagnostic methods, increased awareness of rare diseases, and the availability of enzyme replacement therapy (ERT). Clinical trials and new drug approvals, such as Lysogene's LYS-SAF302 and JCR Pharmaceuticals' JR-141, are pivotal. Despite high treatment costs and reimbursement challenges, the market is set to expand, with ERT remaining the preferred treatment.

JCR Pharmaceuticals announced the first patient dosed in Phase III trial of JR-142, a long-acting growth hormone therapy for pediatric growth hormone deficiency in Japan. The trial involves 54 pediatric patients and aims to compare JR-142's efficacy to JCR's existing product, Growject®, over a 52-week period.

JCR Pharmaceuticals announced the first patient dosed in Phase III trial of JR-142, a long-acting growth hormone therapy for pediatric growth hormone deficiency in Japan. The trial involves 54 pediatric patients and aims to compare JR-142's efficacy to JCR's existing product, Growject®. JR-142 offers potential for once-weekly dosing, easing the burden on children and families.

JCR Pharmaceuticals completes PMDA review for Phase I study of JR-441 for MPS IIIA, using J-Brain Cargo® technology to target neurological symptoms.